Neuroprotective effect and possible mechanism of edaravone in rat models of spinal cord injury: a protocol for a systematic review and meta‑analysis

Systematic Reviews, 2023 · DOI: https://doi.org/10.1186/s13643-023-02306-1 · Published: August 4, 2023

Spinal Cord Injury Neurology Research Methodology & Design

Simple Explanation

Spinal cord injury (SCI) is one of the most disabling neurological conditions. Edaravone, a well-known reactive oxygen species scavenger, is expanding its new scope in field of SCI. The objective of this systematic review is to determine the neuroprotective effects and discuss the underlying mechanism of edaravone in management of SCI. In this study, we aim to quantitatively analyze the role of edaravone in locomotor recovery and tissue damage in SCI rat model.

Study Duration

Not specified

Participants

Experiment rat models

Evidence Level

Systematic review and meta-analysis protocol

Key Findings

1
This systematic review aims to assess the neuroprotective effects of edaravone in experimental SCI and summarize the underlying molecular mechanisms.
2
The primary outcome will be the 21-point Basso, Beattie, and Bresnahan locomotor rating scale.
3
The secondary outcomes will include spared white matter area and malondialdehyde levels.

Research Summary

This study is a protocol for a systematic review and meta-analysis to determine the neuroprotective effects and discuss the underlying mechanism of edaravone in management of spinal cord injury (SCI). The systematic review will include controlled studies evaluating the neurological roles of edaravone on experiment rat models following SCI. The results of this study will construct knowledge framework to understand the neuroprotective effect and possible mechanism of edaravone in management of SCI.

Practical Implications

Preclinical Studies Guidance

The study will help to guide future preclinical studies by identifying optimized parameters for the implementation of these studies.

Clinical Trial Evidence

The study will provide evidence for assessing the prospect of edaravone for future clinical trials and applications in treating SCI.

Mechanism Understanding

The review will produce guidance for the basic research focusing on the in-depth molecular mechanism of edaravone in treating SCI.

Study Limitations

1
The accuracy of this outcome is limited by the assessor subjectivity.
2
A potential risk of bias may be widely appeared in methodological quality of included studies.
3
It is uncertain whether all relevant studies can be identified because we cannot access to all possible databases.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury